✨
AI Summary
- Paul Romness explains OS Therapies' HER2-targeted immunotherapy for pulmonary osteosarcoma.
- Addressing unmet need in a rare pediatric cancer with no standard care.
- Off-the-shelf therapy aims to stimulate robust immune response for better outcomes.
Guests on This Episode
PR
Paul Romness
1 podcast appearance